Altimmune(US:ALT) Prnewswire·2025-09-15 12:45Core Viewpoint - Altimmune, Inc. (NASDAQ: ALT) faces a class action lawsuit following the release of disappointing results from its IMPACT Phase 2b MASH trial, leading to a significant drop in stock price [1]. Group 1: Company Overview - Altimmune, Inc. is currently under scrutiny due to allegations of providing inflated expectations regarding the results of its clinical trial for Pemvidutide, which failed to meet statistical significance in its primary endpoint analysis [1]. - The company's stock price plummeted from $7.71 per share on June 25, 2025, to $3.61 per share on June 26, 2025, marking a decline of 53.2% in just one day [1]. Group 2: Legal Proceedings - Shareholders who purchased shares of ALT between August 10, 2023, and June 25, 2025, are encouraged to register for potential lead plaintiff appointment in the class action lawsuit [1][2]. - The deadline for shareholders to seek lead plaintiff status is October 6, 2025, and there is no cost or obligation to participate in the case [2]. Group 3: Law Firm Involvement - The Gross Law Firm, a nationally recognized class action law firm, is representing the shareholders and aims to protect investors from deceit and fraud [3]. - The firm emphasizes its commitment to ensuring responsible business practices and seeks recovery for investors who suffered losses due to misleading statements from companies [3].